Barclays PLC Grows Stock Position in Zymeworks Inc. (NYSE:ZYME)

Barclays PLC raised its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 43.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 220,890 shares of the company's stock after buying an additional 66,506 shares during the period. Barclays PLC owned approximately 0.32% of Zymeworks worth $3,234,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Zymeworks by 6.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company's stock valued at $214,000 after acquiring an additional 940 shares in the last quarter. Sterling Capital Management LLC raised its position in Zymeworks by 781.5% in the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock valued at $25,000 after purchasing an additional 1,524 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Zymeworks by 19.2% in the 4th quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company's stock valued at $201,000 after buying an additional 2,216 shares during the period. AlphaQuest LLC boosted its stake in shares of Zymeworks by 480.2% in the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock valued at $41,000 after buying an additional 2,324 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Zymeworks by 5.8% during the fourth quarter. Legal & General Group Plc now owns 47,082 shares of the company's stock worth $689,000 after buying an additional 2,590 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Zymeworks Price Performance

Shares of ZYME traded up $0.09 during midday trading on Friday, reaching $12.97. 160,021 shares of the stock were exchanged, compared to its average volume of 612,078. Zymeworks Inc. has a twelve month low of $8.21 and a twelve month high of $17.70. The company has a market capitalization of $902.07 million, a price-to-earnings ratio of -8.64 and a beta of 1.18. The business's 50-day moving average price is $12.02 and its 200 day moving average price is $13.51.

Insiders Place Their Bets

In other Zymeworks news, Director Ecor1 Capital, Llc acquired 73,953 shares of the company's stock in a transaction on Wednesday, April 16th. The shares were bought at an average cost of $11.16 per share, for a total transaction of $825,315.48. Following the completion of the purchase, the director now owns 17,773,727 shares in the company, valued at $198,354,793.32. This trade represents a 0.42 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought a total of 1,350,347 shares of company stock valued at $16,137,499 over the last quarter. Company insiders own 1.92% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZYME. Lifesci Capital started coverage on shares of Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price target for the company. Citigroup lifted their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Finally, HC Wainwright increased their target price on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zymeworks has an average rating of "Moderate Buy" and an average target price of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.